Anaphylaxis is a hyperacute allergic reaction that occurs with increasing incidence in the population and can be of fatal consequence. Symptoms include skin rash, hypotension, hypothermia, abdominal pain, bronchospasm, and heart and lung failure, which can lead to asphyxia and sometimes death. 1 The main treatment remains epinephrine (adrenaline) injection to restore heart and lung function. Because anaphylaxis represents an emergency situation, few clinical studies have been possible to address the mechanisms leading to anaphylaxis in patients. Experimental models of anaphylaxis identified mechanisms involving allergen-specific antibodies that trigger activating antibody receptors on myeloid cells, leading to mediator release. These mediators can, by themselves, recapitulate the symptoms of anaphylaxis observed in human subjects. 2, 3 The ''classical'' mechanism of anaphylaxis states that allergenspecific IgE binds the activating IgE receptor FcεRI on mast cells, which, on allergen encounter, become activated and release histamine, among other mediators. Notably, histamine injection suffices to induce signs of anaphylaxis in animal models. 4 In many cases detectable allergen-specific IgE and increased histamine levels do not accompany anaphylaxis in human subjects (discussed in Khodoun et al 5 ), leading to the notion that ''atypical'' or ''alternate'' mechanisms of induction could explain these cases. One of these atypical/alternate models proposes a similar cascade of events but instead based on allergen-specific IgG binding to allergen, forming IgG-allergen immune complexes that trigger activating IgG Fc receptors (FcgRs) expressed on myeloid cells (ie, macrophages, WT: C57Bl/6 wild-type basophils, and/or neutrophils), which in turn release plateletactivating factor (PAF). 2, 3 Importantly, PAF injection suffices to induce signs of anaphylaxis in animal models. 6 IgG-induced anaphylaxis can be elicited by intravenous injection of allergen-specific IgG followed by allergen administration and is termed IgG-induced passive systemic anaphylaxis (PSA).
IgG receptors in the mouse comprise 4 ''classical'' IgG receptors termed FcgRs but also the neonatal IgG receptor (FcRn) and the intracellular FcR tripartite motif-containing protein 21 (TRIM21). 7, 8 Although FcRn and TRIM21 both participate in the intracellular routing of IgG and FcRn in protection from catabolism and distribution to tissues, 9 FcgRs control cell activation in the presence of immune complexes. FcgRs in mice are subdivided into (1) activating FcgRs (ie, FcgRI, FcgRIII, and FcgRIV), which lead to cell activation on immune complex binding, and (2) an inhibitory FcgR (ie, FcgRIIB), which inhibits cell activation when coengaged by an immune complex with an activating FcgR coexpressed on the same cell. 10 Thus inhibition of cell activation by FcgRIIB requires that the immune complex contains IgG bound by both the activating and inhibitory FcgR.
Four IgG subclasses exist in mice: IgG 1 , IgG 2a , IgG 2b , and IgG 3 . Among those, only IgG 2a and IgG 2b bind to all FcgRs, whereas IgG 1 binds only to FcgRIIB and FcgRIII. It remains under debate whether IgG 3 binds to FcgRs, particularly FcgRI. 11, 12 The affinities of these FcgRs toward IgG subclasses are strikingly different (Table I) , [11] [12] [13] [14] leading to the notion of high-affinity receptors that retain monomeric IgG and low-affinity receptors that do not. 8 However, the avidity of IgG-immune complexes enables both types of receptors to retain IgG-immune complexes, leading to receptor clustering, intracellular signaling events, and, eventually, cell activation. FcgRI is a high-affinity receptor for IgG 2a , 15 and FcgRIV is a high-affinity receptor for IgG 2a and IgG 2b . 16 All other FcgR-IgG interactions are of low affinity (reviewed in Bruhns 7 ). Three of the 4 IgG subclasses in the mouse, IgG 1 , IgG 2a , and IgG 2b , have been reported to enable the induction of systemic anaphylaxis, inducing mild-to-severe hypothermia. 5, 17, 18 This is rather surprising for IgG 1 (Table I) . Notably, FcgRIV is not expressed on basophils but on monocytes/macrophages and neutrophils, 14 which have both been reported to contribute to experimental anaphylaxis. 18, [22] [23] [24] In addition, mice expressing only FcgRIV can develop IgG-dependent PSA. 16 Therefore, together with expression and binding data, one would hypothesize that FcgRIV contributes predominantly to IgG 2a -and IgG 2b -induced PSA.
In this work we present evidence contrary to this hypothesis and reveal which activating FcgR on which cell types releasing which mediators are responsible for IgG 2a -dependent PSA and IgG 2b -dependent PSA and the differential regulation of these models of anaphylaxis by FcgRIIB. Our results unravel a complex balance determined by FcgR expression patterns, inhibition potential by FcgRIIB, and respective affinities of activating and inhibitory FcgRs for IgG subclasses that, together, regulate the contribution of cells and anaphylactogenic mediators to a given model of IgG-induced anaphylaxis.
METHODS Mice
Female C57Bl/6J mice (herein referred to as WT mice) were purchased from Charles River (Wilmington, Mass), female BALB/cJRj mice were from Janvier Labs (Le Genest-Saint-Isle, France), and FcgRIIB Antibodies and reagents PBS and clodronate liposomes were prepared as previously described. 26 Trinitrophenyl (TNP [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 18 Purified mouse IgE anti-TNP was purchased from BD PharMingen (San Jose, Calif). The mAb 9E9 was coupled to fluorescein isothiocyanate (FITC) by using the Pierce FITC Antibody labeling kit (Life Technologies, Grand Island, NY). Antibodies used for flow cytometry staining of c-Kit (clone 2B8), CD49b (clone DX5), IgE (clone R35-72), CD11b (clone M1/70), F4/80 (clone 6F12), CD115 (clone T38-320), Ly6G (clone 1A8), and Ly6C (clone AL-21) were purchased from BD PharMingen; CD45 (clone 30F11) and Gr1 (clone RB6-8C5) were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). FcgRIIB was detected by using the FITC-coupled mAb AT130-2 mIgG1 N297A. IgE-induced PSA. IgE anti-TNP antibodies were administered intravenously at a dose of 50 mg in 200 mL of physiologic saline, followed by an intravenous challenge with 500 mg of TNP-BSA in physiologic saline 24 hours later. The body temperature of mice was monitored with a digital thermometer with a rectal probe (YSI, Yellow Springs, Ohio).
In vivo blocking and cellular depletion
Three hundred microlitres per mouse of PBS or clodronate liposomes, 300 mg/mouse of rat IgG 2b isotype control or anti-Ly6G, and 30 mg/mouse of anti-CD200R3 mAbs were injected intravenously 24 hours before challenge. The specificity of cell depletion was evaluated by using flow cytometry on blood, bone marrow, and splenic and peritoneal cells taken from naive WT mice 24 hours after injection of the depleting antibody or clodronate-liposomes (examples are shown in Figs E1 and E2 in this article's Online Repository at www.jacionline.org). Twenty-five micrograms per mouse of ABT-491 or 300 mg/mouse of cetirizine was injected intravenously 20 minutes or intraperitoneally 30 minutes before challenge, respectively. Two hundred micrograms per mouse of anti-FcgRIV mAb was injected intravenously 30 minutes before challenge.
Flow cytometric analysis
Freshly isolated cells were stained with indicated fluorescently labeled mAbs for 30 minutes at 48C. Cell populations were defined as follows: neutrophils (CD45 
Surface plasmon resonance analysis
Experiments were performed at 258C with a ProteOn XPR36 real-time SPR biosensor (Bio-Rad Laboratories, Hercules, Calif). Anti-TNP antibodies were immobilized covalently through amine coupling on the surface of a GLC chip. TNP-BSA was then injected on the chip at a flow rate of 25 mL $ min 21 
Mast cell histology
Mouse back skin biopsy specimens were collected 24 hours after induction of specific cell depletion, and mouse ear skin biopsy specimens were collected 30 minutes after IgE-, IgG 1 -, IgG 2a -, or IgG 2b -induced PSA and embedded in paraffin before sectioning. Mast cells in toluidine blue-stained biopsy specimens were counted visually in at least 15 fields of view per mouse and more than 6 mice per treatment (see Fig E1, I ).
Statistics
Data were analyzed by using 1-way or 2-way ANOVA with the Tukey posttest. A P value of less than .05 was considered significant. If not stated otherwise, data are represented as means 6 SEMs.
RESULTS

FcgRIII dominates anaphylaxis induced by IgG subclasses
PSA was induced by means of an intravenous injection of one of the different anti-TNP IgG isotypes (IgG 1 , IgG 2a , and IgG 2b ), followed by an intravenous challenge with TNP-BSA 16 hours later. This protocol induces a transient decrease in body temperature that is most pronounced between 30 and 40 minutes. As reported previously, 3, 18, 20, 22, 28 all 3 IgG isotypes were capable of inducing anaphylaxis in WT mice (Fig 1) . In these experimental conditions IgG 1 -induced PSA triggered a maximum temperature loss of approximately 28C, IgG 2a -induced PSA triggered a maximum temperature loss of approximately 48C, and IgG 2b -induced PSA triggered a maximum temperature loss of approximately 38C in WT mice. Using single FcgR knockout mice we evaluated the contribution of each of the 4 mouse FcgRs to these anaphylaxis models. The absence of either FcgRIV (with the exception of a single time point in IgG 2b -induced PSA) or FcgRI had no significant effect on IgG-PSA-induced hypothermia, regardless of the subclass of IgG antibodies used to induce anaphylaxis (Fig 1) . However, the lack of FcgRIII protected mice from anaphylaxis in all models.
Mice lacking the inhibitory receptor FcgRIIB had a significantly more severe temperature decrease than seen in WT mice with IgG 1 -or IgG 2b -induced PSA but showed no significant difference in the severity of IgG 2a -induced PSA (Fig 1) . Even though the 3 anti-TNP IgG mAbs used are not switch variants of a unique anti-TNP antibody, they show comparable binding to TNP-BSA, as determined by using ELISA, and similar affinity (nanomolar range) and dissociation rates (k off ), as determined by using surface plasmon resonance analysis, particularly the IgG 2a and IgG 2b anti-TNP antibodies (see Fig E3, A-C, in this article's Online Repository at www.jacionline.org).
Of note, untreated FcgR-deficient mice presented modest variations in FcgR expression levels (see Fig E4 in FcgRIII is expressed by all myeloid cells 7, 21 and, to a lesser extent, by natural killer (NK) cells. 29 Therefore one might anticipate that IgG immune complexes formed in vivo as a consequence of TNP-BSA injection in anti-TNP-sensitized mice would engage FcgRIII on these cells, leading to cell activation and possibly contributing to anaphylaxis. Basophils, mast cells, neutrophils, and monocyte/macrophages have indeed been reported to contribute to IgG-induced PSA, 17, 18, 20, 22 ; however, the . Significant differences compared with the WT group are indicated. *P < .05, ***P < .001, and ****P < .0001.
FIG 2.
Basophils, mast cells, monocytes/macrophages, and neutrophils contribute differentially to IgGinduced PSA models. Indicated mice (n > _ 8 per group) were injected with IgG 2a (A-E) or IgG 2b (F-J) anti-TNP mAbs and challenged with TNP-BSA, and body temperatures were monitored. WT mice (n 5 8 per group) were pretreated, as indicated (Fig 2, A, C, D , F, H, and I). Lipo-PBS, PBS liposomes; Lipo-Cd, clodronate liposomes. Data are pooled from at least 2 independent experiments. *P <.05, **P <.01, and ****P < .0001.
respective contribution of each of these different cell types remains debated. 2, 28 To investigate which cell types contribute to PSA induced by different IgG subclasses, we depleted basophils (anti-CD200R3 mAb), monocytes/macrophages (clodronatefilled liposomes), or neutrophils (anti-Ly6G) before anaphylaxis induction or evaluated anaphylaxis induction in transgenic mice deficient in certain cell populations.
Of note, the relatively mild temperature loss in WT mice with IgG 1 -induced PSA (see Fig E6, A, in this article's Online Repository at www.jacionline.org) did not allow us to address reliably the contribution of either basophils or neutrophils to this model of anaphylaxis. Therefore we restricted our analysis of the contribution of myeloid cell populations to IgG 2a -and IgG 2b -induced PSA. Antibody-induced basophil depletion or genetically induced mast cell and basophil deficiency (see Fig E2, (Fig 2, A and B) but significantly inhibited IgG 2b -induced PSA (Fig 2, F and G) . Monocyte/macrophage depletion (Fig 2, C and H) significantly inhibited both IgG 2a -and IgG 2b -induced PSA. The absence of neutrophils, either after antibodymediated depletion (Fig 2, D and I) or with neutropenic Gfi1 2/2 mice (Fig 2, E and J) , 30 significantly inhibited both IgG 2a -and IgG 2b -induced PSA. Although monocytes/macrophages and neutrophils appear to contribute to both models of anaphylaxis, basophils and possibly mast cells contribute specifically to IgG 2b -but not IgG 2a -induced PSA.
FcgRIII is downregulated specifically on neutrophils after IgG 2a -induced PSA Khodoun et al 31 proposed to use the reduced expression of FcgRIII on mouse neutrophils as a marker to distinguish IgE-from IgG 1 -induced PSA, both of which required priming with an antigen-specific antibody and challenge with the recognized antigen. Therefore we wondered whether FcgRIII expression on neutrophils might also be a marker for IgG 2a -and IgG 2b -induced PSA. In addition, reduced expression of FcgRs after IgG-induced PSA might document that a particular cell population is activated after engagement of its FcgRs by IgG-immune complexes during anaphylaxis. Thus this parameter can be used to discriminate cell populations contributing to anaphylaxis after direct activation by IgG-immune complexes from those contributing after activation by mediators liberated by IgG-immune complexactivated cells (eg, histamine, PAF, leukotrienes, and prostaglandins).
Among (Fig 3, A and D) . Expression of FcgRIV was also downregulated on neutrophils, but not on Ly6C lo monocytes, during IgG 2a -induced PSA (Fig 3, B and D) . This was unexpected considering that FcgRIV does not significantly contribute to this PSA model (Fig 1, B) . However, FcgRIIB expression remained unchanged on Ly6C hi and Ly6C lo monocytes and neutrophils (Fig 3, C and D) , which is in agreement with the lack of contribution of this receptor to IgG 2a -induced PSA (Fig 1, B) . A-C, FcgRIII (Fig 3, A) , FcgRIV (Fig 3, B) , and FcgRIIB (Fig 3, C) expression on blood cells from WT mice ( Together, these data suggest that neutrophils might be activated directly through FcgRIII by immune complexes formed during IgG 2a -induced PSA. They also suggest that neutrophils, but not Ly6C lo monocytes, can be similarly activated through FcgRIV, even if no contribution of this receptor was identified in this model using FcgRIV 2/2 mice (Fig 1, B) . (2 mg; Fig 4, A) . Already at a dose of 1 mg of IgG 2 , FcgRIII 2/2 mice had mild hypothermia with IgG 2a -but not IgG 2b -induced PSA (Fig 4, B and C) . Unexpectedly, in the same conditions FcgRIV contributed to IgG 2b -induced PSA, which was no longer dampened by inhibitory FcgRIIB (Fig 4, C) . At a dose of 2 mg of IgG, FcgRIII 2/2 mice had hypothermia with both IgG 2a -and IgG 2b -induced PSA, which was abolished when FcgRIII 2/2 mice were pretreated with a blocking antibody against FcgRIV (Fig 4, D and E) . FcgRI did not contribute to either model of IgG 2 -induced PSA at an increased dose (Fig 4,  B and C) . Furthermore, FcgRIII expression was downregulated on neutrophils and basophils, but not on Ly6C hi monocytes, after IgG 2b -induced PSA (Fig 5, A and D) . FcgRIVexpression was also downregulated on neutrophils, but not on Ly6C lo monocytes ( Fig  5, B and D) . However, FcgRIIB expression did not change on either neutrophils or Ly6C hi and Ly6C lo monocytes, even though this inhibitory receptor regulates IgG 2b -induced PSA (Figs 1, C, and 5, C and D). This observation is in agreement with the study by Khodoun et al, 31 which reported that FcgRIIB expression did not change on neutrophils after IgG 1 -induced PSA. Altogether, high doses of antigen-specific IgG 2 reveal the contribution of FcgRIV to IgG 2a -induced PSA and IgG 2b -induced PSA and experiments. Significant differences compared with the untreated WT group are indicated. **P < .01, ***P < .001, and ****P < .0001.
suggest the direct activation of neutrophils and basophils by IgG 2b -immune complexes.
IgG 1 -induced PSA in the absence of inhibitory FcgRIIB
The unexpected differences observed between IgG 2a -and IgG 2b -induced PSA induction pathways prompted us to find a mouse model more sensitive to IgG 1 -induced PSA than WT mice to be able to evaluate the contribution of cell types and mediators in this model. Indeed, as mentioned earlier, WT mice respond poorly in a model of IgG 1 -induced PSA (Fig 1, A, and see Fig E6, A) . 19 However, FcgRIIB 2/2 mice experience a temperature decrease of approximately 48C during IgG 1 -induced PSA, which is comparable with temperature losses observed in WT mice during IgG 2a -or IgG 2b -induced PSA (Fig 1, B and C) . Therefore we analyzed the contribution of cell types to IgG 1 -induced PSA in FcgRIIB 2/2 mice. Basophil depletion mildly but significantly inhibited IgG 1 -induced PSA (Fig 6, A) , which is in agreement with previous data. 20 The depletion of neutrophils had the same effect, although not consistently as strongly as basophil depletion (Fig 6, B, and data not shown) . Monocyte/macrophage depletion had a tendency to ameliorate anaphylaxis that was reproducible but not significant (Fig 6, C) . These results suggest that IgG 1 -induced PSA relies on basophils and neutrophils and possibly also monocytes.
PAF and histamine contribute differentially to IgG 2a -and IgG 2b -induced PSA Because cell types contribute differently to IgG 2 -induced PSA models (ie, IgG 2a -induced PSA for neutrophils and monocytes and IgG 2b -induced PSA for basophils, neutrophils, and monocytes), one can expect that the mediators responsible for clinical signs also might differ between them. PAF has been shown to be responsible for anaphylactic reactions that required basophil, 20 neutrophil, 18, 24 and/or monocyte/macrophage 22 activation, whereas histamine has been shown to be responsible for mast cell-and basophil-dependent anaphylaxis. 35, 36 Neutrophils are the main producers of PAF, 37 whereas mast cells and basophils are the main producers of histamine.
38,39 Therefore we analyzed the relative contribution of these 2 mediators to the 3 models of PSA by using the histamine receptor 1 antagonist cetirizine and the PAF receptor antagonist ABT-491. Surprisingly, the histamine receptor 1 antagonist cetirizine significantly inhibited IgG 1 -induced PSA, whereas the PAF receptor antagonist ABT-491 had no significant effect, which is in opposition to previous data. 20 The combination of both antagonists had an additive effect and almost abolished IgG 1 -induced PSA (Fig 7, A) . The results obtained in FcgRIIB 2/2 mice were confirmed in WT mice (Fig 7, A) . Whereas cetirizine mildly reduced hypothermia in IgG 2a -induced PSA, it significantly inhibited IgG 2b -induced PSA. ABT-491 mildly reduced hypothermia in mice with IgG 2a -induced PSA but had no significant effect on mice with IgG 2b -induced PSA (Fig 7, B and C) . However, the combination figure 1 or 0.5 mg of IgG 2b was injected to assess expression on neutrophils/monocytes or basophils, respectively. *P <.05, **P <.01, and ****P <.0001.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 of cetirizine and ABT-491 almost abolished both IgG 2a -and IgG 2b -induced PSA. Increased plasma histamine levels were detected 5 minutes after challenge in all 3 IgG-induced PSA models, and particularly high levels were observed in mice undergoing IgE-induced PSA (as a positive control) or IgG 2a -induced PSA (Fig 7, D and E) . This latter finding is surprising because IgG 2a -induced PSA is unaffected by the absence of both mast cells and basophils, which are considered major sources of histamine. mMCP-1, which is released on activation of mucosal mast cells, could be detected in the sera of mice undergoing IgE-induced PSA but not in those undergoing any one of the 3 models of IgG-induced PSA 3 hours after PSA induction (Fig 7, F) . Collectively, these results suggest that histamine predominantly contributes to IgG 1 -and IgG 2b -induced PSA, whereas histamine and PAF together are necessary for IgG 2a -induced PSA. In support of the notion that FcgRIII predominates in IgGinduced PSA induction, an alternative model of PSA induced by sensitization and challenge with goat antibodies was found to be driven by FcgRIII, 22 and blocking antibodies against FcgRIII were protective in a model of PSA induced by IgG immune complexes. 18 In addition, IgG 2a -induced PSA in FcgRIIB 2/2 mice was abolished after injection of anti-FcgRIIB/III blocking mAbs. 5 FcgRIII is the only activating IgG receptor in the mouse that does not bind an IgG subclass with high affinity, and thus it remains unoccupied by monomeric IgG and accessible for binding of immune complexes. This is theoretically not the case for FcgRI and FcgRIV, which at physiologic serum concentrations of IgG 2a (approximately 2.5 mg/mL) and IgG 2b (approximately 1.5 mg/mL), are likely occupied in vivo, particularly on circulating cells. Of note, C57Bl/6 mice produce IgG 2c but not IgG 2a antibodies, the amino acid sequence of which varies by about 15%. Experiments performed in BALB/c mice that express endogenous IgG 2a (but no IgG 2c ) produced similar results regarding the contribution of basophils, neutrophils, and monocytes to IgG 2a (see Fig E6, B) , indicating that IgG 2a and IgG 2c sequence variations probably do not affect the mechanisms of anaphylaxis induction that we describe herein.
DISCUSSION
Adult female mice of 20 g, as used in this study, possess a circulating blood volume of 1.4 to 1.5 mL. Injection of 500 mg of antibody thus corresponds to approximately 330 mg/mL of circulating antibody, injection of 1 mg corresponds to approximately 660 mg/mL, and injection of 2 mg corresponds to approximately 1.3 mg/mL. In cases of anaphylaxis, the circulating concentration of allergen-specific IgG has not been evaluated because of a lack of testing and appropriate controls (ie, antiallergen mAbs), although we have reported high circulating antigen-specific IgG levels in an autoimmune model of arthritis. injection of polyclonal anti-sera, followed by antigen challenge. 18 We reported previously that IgG 2b -induced PSA triggered by injection of preformed IgG 2b -immune complexes in WT mice was abolished after injection of anti-FcgRIV blocking mAb 9E9. 18 This contrasts with the findings of the current study, in which we show that FcgRIII is the major activating receptor in all models of IgG-induced PSA and FcgRIV contributes only at high antibody concentrations. Two hypotheses might explain these discrepant results: (1) the injection of preformed IgG 2b -immune complexes leads to an immediate circulating bolus of immune complexes, which are similarly formed only after injection of high amounts of IgG 2b and antigen, thus triggering FcgRIV, and (2) as recently reported, 40 mAb 9E9 might not only block FcgRIV through its Fab portions but also FcgRIII through its Fc portion once 9E9 is bound to FcgRIV. In our view it is likely that a combination of these mechanisms reconciles our previous and herein described results and suggest that IgG 2b PSA induced after injection of preformed IgG 2b -immune complexes relies on both FcgRIII and FcgRIV rather than on FcgRIValone, as we reported previously. 18 Together, this body of evidence supports the notion that FcgRIV is capable of triggering cell activation leading to anaphylaxis, although in restricted conditions (ie, in the absence/blockade of FcgRIII or presence of large amounts of IgG 2a and/or IgG 2b antibodies).
The differential contribution of FcgRs to IgG-induced PSA might rely on their respective expression patterns on myeloid cells. Indeed, FcgRI is not 32, 33 or is only barely 34 expressed on circulating monocytes, and its expression is largely restricted to tissue-resident macrophages. Therefore the level of its expression on cells reported to contribute to anaphylaxis (ie, monocytes in (Fig 7, A) , IgG 2a -induced PSA (Fig 7, B) , IgG 2b -induced PSA (Fig 7, C) or IgE-induced PSA (Fig 7, D) in WT mice (n > _ 7 per group). E and F, Histamine (Fig 7, E) and mMCP-1 (Fig 7, F) concentrations after PSA (n 5 3 per group). Data are representative of at least 2 independent experiments, except for Fig 7, A and C (pooled from 2 independent experiments). *P < .05, **P < .01, ***P < .001, and ****P < .0001.
this case) might not suffice to induce their activation. This notion is supported by the absence of any detectable effect of FcgRI deficiency in the mice with IgG 2 -induced PSA on which we report in this study, even at high doses of IgG 2 antibodies. However, FcgRIII is expressed on all myeloid cells 7 and, moreover, at comparably high levels on all those cell types that have been reported to contribute to anaphylaxis: basophils, monocytes, and neutrophils. 21 This pattern of cellular expression might explain its predominant contribution to all models of IgG-induced anaphylaxis. FcgRIV is expressed on neutrophils and Ly6C lo monocytes. However, it remains unclear whether Ly6C lo , Ly6C hi , or both monocyte subsets contribute to anaphylaxis. FcgRIV could contribute to PSA induction in exceptional conditions (FcgRIII deficiency or high IgG 2 antibody doses). The lack of FcgRIV contribution in classical conditions of PSA might suggest that its expression level is not sufficient in WT mice. Notably, it has been reported previously that particular FcgR deficiencies modify the expression levels of other FcgRs. In particular, FcgRIII 2/2 mice, but not FcgRI 2/2 mice, presented a significant increase in FcgRIV expression levels on neutrophils 18, 41, 42 and a tendency for increased expression on Ly6C lo monocytes (see Fig  E4, B) . This could explain why the contribution of FcgRIV to IgG 2 -induced PSA becomes apparent in FcgRIII 2/2 mice. Conversely, FcgRIV 2/2 mice did not present alterations of FcgRIII expression on neutrophils or Ly6C hi monocytes compared with WT littermates (see Fig E4, A) . FcgRIIB 2/2 mice expressed significantly higher levels of FcgRIII and FcgRIV on neutrophils and increased FcgRIII levels on Ly6C hi monocytes that might, altogether, contribute to their higher susceptibility to anaphylaxis induction (see Fig E4, A and B) .
The contribution of a rather restricted subset of myeloid cells to these (and other) models of anaphylaxis 2,3 appears to be determined by at least 2 factors: their capacity to release anaphylactogenic mediators (eg, histamine or PAF) and their expression of sufficient levels of activating IgG receptors. Mast cells and basophils release histamine, and neutrophils monocytes/macrophages, and basophils release PAF on FcgR triggering. Other mediators might induce anaphylaxis or contribute to its severity, among them lipid mediators, such as prostaglandins, thromboxanes, and leukotrienes. Indeed, some of these have been reported to trigger bronchoconstriction and an increase in vascular permeability. 43 The release of such mediators is sufficiently rapid to coincide with the celerity of hypothermia, which is detectable within minutes after allergen challenge. Therefore it is surprising that eosinophils do not contribute to IgG-induced PSA because they express high levels of activating FcgRIII and FcgRIIB 21 (but no FcgRI or FcgRIV) and are capable of releasing leukotriene C 4 , prostaglandin E 2 , thromboxane, and PAF on activation. 43 Although eosinophils appear in relatively low numbers among blood cells (approximately 2 3 10 5 /mL), this is an unlikely explanation because basophils are significantly less numerous (approximately 5 3 10 4 /mL) but do contribute to anaphylaxis models. Most revealingly, it has been reported that eosinophils do not release PAF after IgG-dependent activation. 44 Whether eosinophils produce other potentially anaphylactogenic mediators after IgG-immune complex activation has not been investigated, but the lack of such an effect appears the most reasonable hypothesis to explain why eosinophils have not been found to contribute to IgG-induced anaphylaxis.
We investigated the contribution of neutrophils and monocytes to IgG-induced PSA models by using depletion approaches.
Ly6G
1 cell depletion with NIMP-R14 resulted in an efficient depletion of neutrophils in the blood and spleen (see Figs E1 , B, and E2, B). The same treatment resulted only in partial depletion in the bone marrow, in which a proportion of Ly6G 1 cells are masked from fluorescent anti-Ly6G staining but not depleted by NIMP-R14 treatment (refer to bone marrow panels in Figs E1,  C and D, and E2, C, D, and I) . Importantly, we found that NIMP-R14 depletion has a significant effect on monocyte populations in the blood and, to some extent, in the spleen. This should be taken into consideration when interpreting the results of NIMP-R14 depletion experiments. All IgG-induced PSA models were ameliorated after NIMP-R14 depletion but also when monocytes/macrophages were targeted by using clodronate liposomes. Intravenous injection of clodronate liposomes resulted in a significant depletion of monocytes from the blood and monocytes/macrophages from the spleen and bone marrow but not from the skin (data not shown) and peritoneum (see Figs E1 and E2, as previously reported 26 ) and to a significant increase in blood leukocyte counts, particularly neutrophils (see Figs E1 and E2 ). Thus the anti-Ly6G and clodronate liposome treatments alter also monocytes and the neutrophil compartment, respectively, but reduce hypothermia in the 3 models of IgG-induced PSA studied. Constitutive deficiency in neutrophils, as studied with Gfi1 2/2 mice, confirmed the role of neutrophils in IgG 2a -and IgG 2b -induced PSA models. Therefore both neutrophils and monocytes can be considered to contribute to IgG-induced anaphylaxis in mice, whether dependent on IgG 1 , IgG 2a , or IgG 2b . The role of macrophages in the different IgG-induced PSA models remains to be investigated more deeply because clodronate liposomes injected intravenously efficiently targeted macrophages in the spleen but not in other tissues, such as the peritoneum or skin, and this does not allow conclusions on their contribution.
The contribution of basophils to models of anaphylaxis has been a recent matter of debate. Tsujimura et al 20 reported that depletion of basophils with anti-CD200R3 (clone Ba103) mAbs strongly inhibited IgG 1 -induced PSA and rescued mast cell-deficient mice from active anaphylaxis. However, Ohnmacht et al 45 found that basophil-deficient Mcpt8 cre mice demonstrated slightly decreased but significant hypothermia in response to IgG 1 -induced PSA (induced with the same antibody clone) when compared with WT mice. More recently, Reber et al 36 reported that peanutinduced anaphylaxis was reduced after diphtheria toxin injection in Mcpt8 DTR mice, which selectively depletes basophils, and confirmed that basophil depletion with anti-CD200R3 mAbs inhibited anaphylaxis. Moreover, Khodoun et al 5 found a contribution of basophils to anaphylaxis-related mortality but not to hypothermia in a model of IgG 2a -induced PSA after anti-CD200R3 mAb injection. Therefore it appears that differences between inducible basophil depletion with specific antibodies or toxin administration and a constitutive lack of basophils, possibly leading to compensatory mechanisms during development of these mice, might account for the divergent results observed. However, intriguingly, basophils have been reported to be resistant to IgG-immune complex triggering ex vivo because of dominant inhibition by FcgRIIB over activation by FcgRIII. 21 In this study we report that both basophil depletion after anti-CD200R3 mAb (Ba103) injection or constitutive deficiency of basophils and mast cells in Cpa3-Cre; Mcl-1 fl/fl mice inhibits IgG 2b -induced PSA but not IgG 2a -induced PSA, confirming a role for basophils (and potentially mast cells) to specific IgGinduced PSA models. Of note, Ba103 efficiently depleted basophils from the blood and partially from the spleen and the bone marrow but had no significant effect on mast cells in the peritoneum or skin (see Figs E1, A and E, and E2, A and E). The difference in the ability of basophils to respond to IgG-immune complex triggering in vitro and the various in vivo models might be explained by functional alterations during basophil purification or a requirement for costimulation by other cells or their products that are present in vivo, but not ex vivo, for basophils to respond to IgG-immune complexes.
Our results with Cpa3-Cre; Mcl-1 fl/fl mice indicate that mast cells were not necessary for IgG 2a -induced PSA. We could not formally define their role in IgG 2b -induced PSA because basophil depletion and deficiency in basophils and mast cells lead to similar reduction in IgG 2b -induced PSA. Notably, increased plasma histamine levels, but no increase in mMCP-1 levels, could be detected, suggesting that mucosal mast cells were not activated during IgG-induced PSA. Intriguingly, however, some dermal mast cells displayed a degranulated morphology 30 minutes after challenge in all IgG-induced PSA models tested (for examples see Fig E7 in this article's Online Repository at www.jacionline.org). However, whether their degranulation is a cause or a consequence of anaphylaxis remains elusive. 17 The ability of cells expressing activating FcgRs to respond to IgG-immune complexes has been proposed to be regulated by coexpression of FcgRIIB. 46 (Table I) . Another factor might be the variance in expression of FcgRIIB on circulating myeloid cells as follows: basophils > monocytes > eosinophils >> neutrophils. 21 Although the exact numbers of expressed activating FcgRIII and inhibitory FcgRIIB per cell remain unknown, flow cytometric analysis allowed the estimation of their relative expression: indeed, the FcgRIII/ FcgRIIB ratio is higher on neutrophils than on monocytes and basophils. Thus these differential expression levels might explain why neutrophils contribute to anaphylaxis because the receptor balance is in favor of the activating receptor. Strikingly, FcgRIIB is coexpressed only with FcgRIII on basophils and Ly6C hi monocytes, whereas it is coexpressed with FcgRIII and FcgRIV on neutrophils and Ly6C lo monocytes. 34 Therefore contribution of a given cell type to anaphylaxis might be favored when inhibitory FcgRIIB is required to dampen the stimulatory potential of 2 activating IgG receptors instead of 1. This concept extends to IgG 1 -immune complexes that only engage one activating receptor, FcgRIII.
Our results on the contribution of mouse IgG receptors, cells, and mediators in the setting of IgG-induced anaphylaxis can potentially be translated to human IgG-dependent anaphylaxis (eg, after intravenous IgG or therapeutic IgG antibody administration). Indeed, even though IgG receptors are different in the 2 species, we have already reported that human FcgRI and human FcgRIIA can induce anaphylaxis when expressed under the control of their own promoter in transgenic mice. 23, 24 Human FcgRI (CD64) is the equivalent of mouse FcgRI, whereas human FcgRIIA (CD32A) can be regarded as the equivalent of mouse FcgRIII, and human FcgRIIIA (CD16A) is the equivalent of mouse FcgRIV. 7 Human FcgRIIA, like mouse FcgRIII, is expressed on all myeloid cells and could therefore act as the principal IgG receptor responsible for anaphylaxis in human subjects. Human FcgRIIB, the equivalent of mouse FcgRIIB, is scarcely expressed on most circulating myeloid cells, 47 except for its high expression on basophils, 21 suggesting that among myeloid cells, only human basophils are highly sensitive to human FcgRIIB-mediated inhibition. In contrast to mouse FcgRI, human FcgRI is constitutively expressed on circulating monocytes and inducibly on neutrophils, allowing this receptor to induce anaphylaxis. 24 The 48 If we consider the translation of our results obtained in the mouse to human IgG-induced anaphylaxis, one could anticipate that human FcgRIIB-mediated inhibition of IgG-induced anaphylaxis is inefficient in human neutrophils and monocytes and efficient only in human basophils for which increased human FcgRIIB expression might compensate for the low-affinity version of this receptor for human IgG subclasses. Certainly, FcgR engagement by IgG immune complexes on human basophils could not trigger any detectable basophil activation in vitro, 21 which is similar to the results we reported for mouse basophil activation. Altogether, our data propose that the differential expression of inhibitory FcgRIIB on myeloid cells and its differential binding of IgG subclasses control the contribution of basophils, neutrophils, and monocytes to IgG-dependent anaphylaxis, thus revealing novel complexities in the mechanism of regulation of cell populations and therefore their contribution to IgG-induced reactions in vivo.
Clinical implications: Anaphylactic pathways induced by different IgG subclasses in mice vary in terms of contributions by different cell types, mediators, and antibody receptors. These results might help in the design of efforts to understand and treat IgG-induced anaphylaxis in human subjects, such as those seen after intravenous IgG or administration of therapeutic IgG antibodies.
FIG E1.
Effects of depletion strategies on myeloid cell populations: cell counts. WT mice were treated with indicated reagents. Twenty-four hours after injection, counts of specific cell populations were determined by means of flow cytometry (A-G) or histology (I and J), and leukocyte counts in total blood were measured with an automatic blood analyzer (H): counts of basophils (Fig E1, A) , neutrophils (Fig E1, B) , Ly6C hi monocytes (Fig E1, C) , and Ly6C lo monocytes (Fig E1, D) in blood, spleen, and bone marrow; peritoneal mast cells (Fig E1, E) ; peritoneal macrophages ( Fig E1, F) ; and splenic macrophages (Fig E1, G) . I, Representation of a toluidine blue-stained back skin section with 2 mast cells (arrows). J, Counts of mast cells per square millimeter in the dermis of WT mice. Fig E1, A-H, show 1 of 3 independent experiments. Individual measurements and means 6 SEMs are represented. Ba103, Anti-CD200R3 mAb; CS, clodronate liposomes; Iso, isotype rat IgG 2b ; NIMP, anti-Ly6G mAb; PBS, PBS liposomes.
FIG E2.
Effects of depletion strategies on myeloid cell populations: frequencies. WT mice were treated with indicated reagents. A-G, Twenty-four hours after injection, percentages of specific cell populations among CD45 1 cells were determined by means of flow cytometry: basophils (Fig E2, A) , neutrophils ( Fig   E2, B) , Ly6C hi monocytes (Fig E2, C) , and Ly6C lo monocytes (Fig E2, D) in blood, spleen, and bone marrow; peritoneal mast cells (Fig E2, E) ; peritoneal macrophages ( Fig E2, F) ; and splenic macrophages (Fig E2, G) . A representation of a toluidine blue-stained ear skin section with 1 mast cell (indicated by an arrow) for 1 mouse of each group of mice is shown.
